ApoE promotes the proteolytic degradation of Abeta - Test2 - elhamkhani - TriplyDB

ApoE promotes the proteolytic degradation of Abeta

ApoE promotes the proteolytic degradation of Abeta

http://www.wikidata.org/entity/Q24651102

about

Transthyretin and the brain re-visited: is neuronal synthesis of transthyretin protective in Alzheimer's disease?Gene transfer of human Apoe isoforms results in differential modulation of amyloid deposition and neurotoxicity in mouse brain Human APOE genotype affects intraneuronal Aβ1-42 accumulation in a lentiviral gene transfer model Impact of apolipoprotein E on Alzheimer's disease Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy Apolipoprotein E receptors in the nervous system MyD88 deficiency ameliorates β-amyloidosis in an animal model of Alzheimer's disease ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models Genetic and Transcriptomic Profiles of Inflammation in Neurodegenerative Diseases: Alzheimer, Parkinson, Creutzfeldt-Jakob and Tauopathies Impaired vascular-mediated clearance of brain amyloid beta in Alzheimer's disease: the role, regulation and restoration of LRP1 Body fluid biomarkers in Alzheimer's disease Apolipoprotein E and apolipoprotein E receptors: normal biology and roles in Alzheimer disease Genetic psychophysiology: advances, problems, and future directions Towards understanding the roles of heparan sulfate proteoglycans in Alzheimer's disease Oxidized cholesterol as the driving force behind the development of Alzheimer's disease Impact of age on the cerebrovascular proteomes of wild-type and Tg-SwDI mice The liver X receptor agonist GW3965 improves recovery from mild repetitive traumatic brain injury in mice partly through apolipoprotein E ACAT1/SOAT1 as a therapeutic target for Alzheimer's disease Neuroinflammation in Alzheimer's disease Beta-amyloid deposition and the aging brain A Genetic Variant of the Sortilin 1 Gene is Associated with Reduced Risk of Alzheimer's Disease Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy Statins promote the degradation of extracellular amyloid {beta}-peptide by microglia via stimulation of exosome-associated insulin-degrading enzyme (IDE) secretion Interactions between inflammation, sex steroids, and Alzheimer's disease risk factors Defensive effect of lansoprazole in dementia of AD type in mice exposed to streptozotocin and cholesterol enriched diet Identification of a Chrysanthemic Ester as an Apolipoprotein E Inducer in Astrocytes Effect of LXR/RXR agonism on brain and CSF Aβ40 levels in rats Allopregnanolone promotes regeneration and reduces β-amyloid burden in a preclinical model of Alzheimer's disease Genetic evidence implicates the immune system and cholesterol metabolism in the aetiology of Alzheimer's disease Comment on "ApoE-Directed Therapeutics Rapidly Clear -Amyloid and Reverse Deficits in AD Mouse Models"PET amyloid-beta imaging in preclinical Alzheimer's disease Diet intervention and cerebrospinal fluid biomarkers in amnestic mild cognitive impairment.The Neurobiology and Age-Related Prevalence of the ε4 Allele of Apolipoprotein E in Alzheimer's Disease Cohorts.Overexpression of low-density lipoprotein receptor in the brain markedly inhibits amyloid deposition and increases extracellular A beta clearance Low-density lipoprotein receptor represents an apolipoprotein E-independent pathway of Aβ uptake and degradation by astrocytes Specific loss of brain ABCA1 increases brain cholesterol uptake and influences neuronal structure and function.Allele-specific RNAi mitigates phenotypic progression in a transgenic model of Alzheimer's disease.Adeno-associated virus gene therapy with cholesterol 24-hydroxylase reduces the amyloid pathology before or after the onset of amyloid plaques in mouse models of Alzheimer's disease.ATP-binding cassette transporter A1 mediates the beneficial effects of the liver X receptor agonist GW3965 on object recognition memory and amyloid burden in amyloid precursor protein/presenilin 1 mice.Attenuating astrocyte activation accelerates plaque pathogenesis in APP/PS1 mice.

P2860

Q21202832-5FEB6CE4-D2CA-460A-9DBB-CDDDB3B62B79 Q24308258-3AED315E-E4DF-4BAC-B180-A0509BAA6D9B Q24338827-B6EDAB99-D6E8-49CB-A3BD-FB1C8E085825 Q24567759-6CBB4FA0-460F-4009-A12B-0341318DB288 Q24604376-CBC9125F-2E33-45B0-B7AE-E9A1FE924E32 Q24607165-3E51BB0E-4014-4EF1-96FE-7D1FF0B17AC9 Q24616286-7D35CA14-7E89-414A-B36A-F1D6F9229F13 Q24628845-EA47FED9-2588-4464-9057-631E8E787576 Q26767289-0CE16C60-5B6A-4516-99E9-1ED0E6507D7E Q26800063-59F0C134-A7B3-4335-B45F-D411931FBB58 Q26830098-05EBE602-7D44-47C2-9AC7-5EF7D8CADA50 Q26858870-739AF5EC-AA96-4710-8F67-438CEC31B91D Q26863517-7E86674B-0D7C-4EC1-93E2-0269E2C0471A Q26992202-89C415B7-E550-40F1-B478-B99454027172 Q27023315-4EFFA30C-788B-4E6B-95D1-01301EF7F1CC Q27319555-D6936DED-D4C0-489F-873A-AA8C1BE43EF8 Q27321301-857F5304-213B-4C14-9B01-4714C0D49281 Q28081654-EEE029D4-4E5A-47E1-91D8-257282B843D9 Q28259238-5BBA8FE3-9189-4802-9A8C-E2A8B05CF72B Q28264556-BB4286AC-5BB3-4867-9195-DA5DA732CF4E Q28276977-435F5D0C-247B-4ED4-92AF-131C325ABC7F Q28282855-BB1A9A45-0D6A-4D46-878F-668DEBD79CE0 Q28294279-6BBD4C3C-2717-40C2-BC14-B724A32C372E Q28394967-1D61272A-12CE-4F72-B316-AB9A977CF334 Q28535014-B76CE2BF-05DC-450A-96A1-46E26844C0C9 Q28553918-A30A1012-078F-48BF-B055-B541D75F8534 Q28602802-BC42FD1D-F7B4-4F9B-A499-91F424BC7791 Q28740634-6E65BD43-9CF6-4095-AEE6-10D28837ADF0 Q28748461-91A0B551-CD70-4A32-8700-745C16D743A7 Q29013008-6C34A877-1185-45D1-91CF-538FDA59E764 Q30040695-2596ED13-C41B-44D1-B91A-1DA3C2728CC0 Q30052936-E85E6D47-23EE-44FB-A322-A69567E5F650 Q30248596-5DD7C80B-6084-4D01-91C9-37522DC80F86 Q30274556-697BB757-399B-4EA5-8E69-0F93A641EFD5 Q30274560-67984134-CEAF-4252-8D5A-D7F7F6D333AB Q30486577-744F9A0F-53AD-4920-892D-ABE3C333FEE0 Q30493543-9ADFE9D6-D658-40C3-AFA6-DC969AECC33D Q30493684-4E5B4D01-F1CA-46B0-BBC5-9B0DF0E93EE2 Q30497102-A3C59B59-51A6-47E5-A0C0-3DAD289D9205 Q30530388-085849C0-39AD-49AC-A92E-F1B9D496A505

P2860

ApoE promotes the proteolytic degradation of Abeta

http://www.wikidata.org/entity/Q24651102

description

2008 nî lūn-bûn

@nan

2008 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

ApoE promotes the proteolytic degradation of Abeta

@ast

ApoE promotes the proteolytic degradation of Abeta

@en

ApoE promotes the proteolytic degradation of Abeta

@nl

type

label

ApoE promotes the proteolytic degradation of Abeta

@ast

ApoE promotes the proteolytic degradation of Abeta

@en

ApoE promotes the proteolytic degradation of Abeta

@nl

prefLabel

ApoE promotes the proteolytic degradation of Abeta

@ast

ApoE promotes the proteolytic degradation of Abeta

@en

ApoE promotes the proteolytic degradation of Abeta

@nl

P1433

Q24651102-A21A4212-562F-4690-B360-C8E5EBE818C9

P1476

Q24651102-4E13FC85-38C1-48FD-91AE-3DC8DF31B97A

P2093

Q24651102-09598834-35D2-41E3-8107-DF7C249A6E3B

Q24651102-1CF10393-FC10-4A8D-94D7-402219BE69E7

Q24651102-4A041EC9-1B85-49D4-B26A-78113DCDB919

Q24651102-57AF375E-BDFA-4826-8C00-C650466659E6

Q24651102-7821BE2A-20D8-4A38-9FF9-01F67BC912CD

Q24651102-7FB21919-B448-47C9-86AB-E4A142AE7BBF

Q24651102-8AC8DA72-9964-469E-92F3-57675CDAECD4

Q24651102-8BEC7F30-026D-4B29-8DB8-89670B240DAC

Q24651102-9543A322-21CC-4786-BBCF-641F3E93E34E

Q24651102-BD6E8D8D-9611-48F9-B701-50F1314E988F

P2860

Q24651102-019D84B8-F0AD-44A4-9284-A7CAFBF2F0C3

Q24651102-04DB0913-EA4E-4CC6-B0BB-1A25A3E9806C

Q24651102-0634186F-543A-4779-BB45-B97357CB4033

Q24651102-06858CF1-A885-4689-9108-EF7A256E3DE9

Q24651102-09EA71C9-EBE0-497F-B299-86FCEDCEAE38

Q24651102-0EC8001B-29E6-49DD-98DA-D0DE6F1CAEAE

Q24651102-101C9217-66DD-426C-A5BF-BE31D7808BC6

Q24651102-12D69707-445B-4C8A-B12D-E0ABACB3E4D2

Q24651102-150F9D48-640C-4653-A2FB-B096C6D8FCC7

Q24651102-16083247-6310-49C3-B860-F343B1C5B8A2

P304

Q24651102-A280DFA5-8ACD-4291-A00E-62110961088E

P31

Q24651102-773DEE26-317B-4F6E-98C5-94173F087CFC

P3181

Q24651102-FDE12919-3A71-4E08-98ED-5FF464F8FCE9

P356

Q24651102-242B3226-566E-4411-B1F4-3672DC00CDDF

P407

Q24651102-E030DDEE-F789-4540-9CC6-622C3D1F9BB8

P433

Q24651102-1F077FBE-4DDC-4EE9-B34E-C94F28E9ECD5

P478

Q24651102-D4E61223-E2AF-486E-9FDC-FC866F8A3197

P50

Q24651102-72826456-F9AB-4847-BF71-B72DBDFD40AF

Q24651102-A31C6539-4B74-4747-8976-3BD85BB695D5

P577

Q24651102-2F36A555-70C6-4E7B-B01C-9785DC3EAC8A

P5875

Q24651102-595CDA98-46BC-458A-8C6A-AE31FDDB58EC

P698

Q24651102-A5A18DD0-415D-425B-B221-2A0B6E52CCC2

P921

Q24651102-0A284EC0-A683-4826-B261-6E949353361C

P932

Q24651102-BDD7C17D-F347-4B72-A0B4-AEAC3F83D7CF

P3181

P356

J.NEURON.2008.04.010

P1433

P1476

ApoE promotes the proteolytic degradation of Abeta

@en

P2093

Brandy Wilkinson

http://www.w3.org/2001/XMLSchema#string

Bruce Lamb

http://www.w3.org/2001/XMLSchema#string

C Y Daniel Lee

http://www.w3.org/2001/XMLSchema#string

David Riddell

http://www.w3.org/2001/XMLSchema#string

Gary E Landreth

http://www.w3.org/2001/XMLSchema#string

Jill C Richardson

http://www.w3.org/2001/XMLSchema#string

Jon L Collins

http://www.w3.org/2001/XMLSchema#string

Jonathan D Smith

http://www.w3.org/2001/XMLSchema#string

Karen Mann

http://www.w3.org/2001/XMLSchema#string

Noam Zelcer

http://www.w3.org/2001/XMLSchema#string

P2860

Insulin-degrading enzyme regulates extracellular levels of amyloid beta-protein by degradation

Apolipoprotein A-I directly interacts with amyloid precursor protein and inhibits A beta aggregation and toxicity

ABCA1 mediates concurrent cholesterol and phospholipid efflux to apolipoprotein A-I

Liver X receptors in the central nervous system: from lipid homeostasis to neuronal degeneration

Human amyloid-beta synthesis and clearance rates as measured in cerebrospinal fluid in vivo

Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo

The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics

Identification of the major Abeta1-42-degrading catabolic pathway in brain parenchyma: suppression leads to biochemical and pathological deposition

Alzheimer's beta-amyloid peptide specifically interacts with and is degraded by insulin degrading enzyme

The liver X receptor ligand T0901317 decreases amyloid beta production in vitro and in a mouse model of Alzheimer's disease

P304

681-93

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1215828

http://www.w3.org/2001/XMLSchema#string

P356

10.1016/J.NEURON.2008.04.010

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

58

http://www.w3.org/2001/XMLSchema#string

P50

David M. Holtzman

P577

2008-06-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5306856

http://www.w3.org/2001/XMLSchema#string

P698

18549781

http://www.w3.org/2001/XMLSchema#string

P921

P932

2493297

http://www.w3.org/2001/XMLSchema#string